Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Abstract

Compositions and methods for treating MM are provided herein.

1 - 63 . (canceled) 
     
     
         64 . A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody and a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide. 
     
     
         65 . The method of  claim 64 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1. 
     
     
         66 . The method of  claim 64 , wherein the anti-CS1 antibody binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1. 
     
     
         67 . The method of  claim 64 , wherein the anti-CS1 antibody is a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         68 . A method of treating multiple myeloma in a subject, the method comprising administering to a subject in need thereof (a) an anti-CS1 antibody that binds the epitope cluster covered by amino acids 170 to 227 of SEQ ID NO:1, and (b) two more therapeutic agents, wherein said two more therapeutic agents consist of dexamethasone and bortezomib. 
     
     
         69 . The method of  claim 68 , wherein the anti-CS1 antibody, the dexamethasone and the bortezomib are provided in three separate pharmaceutical compositions. 
     
     
         70 . The method of  claim 69 , wherein the three pharmaceutical compositions are administered separately or concurrently. 
     
     
         71 . The method of  claim 70 , wherein the three pharmaceutical compositions are administered separately. 
     
     
         72 . The method of  claim 69 , wherein the anti-CS1 antibody is a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         73 . The method of  claim 72 , in which the anti-CS1 antibody is administered intravenously at a dose from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         74 . The method of  claim 72 , in which the anti-CS1 antibody is administered intravenously at a dose of approximately 10 mg/kg. 
     
     
         75 . The method of  claim 72 , wherein the bortezomib is administered twice weekly over a 21 day cycle followed by a 10 day rest period. 
     
     
         76 . The method of  claim 72 , wherein the anti-CS1 antibody administered once every 10 days. 
     
     
         77 . The method of  claim 72 , wherein the anti-CS1 antibody is administered as an intravenous infusion at a dose from 2.5 mg/kg to 20 mg/kg and wherein the bortezomib is administered as an intravenous infusion at a dose from 0.2 mg/m 2  to 2.0 mg/m 2 . 
     
     
         78 . The method of  claim 77 , wherein the bortezomib is administered at an intravenous dose from 1.0 mg/m 2  to 1.3 mg/m 2 . 
     
     
         79 . The method of  claim 78 , wherein the bortezomib is administered at an intravenous dose of 1.0 mg/m 2 . 
     
     
         80 . The method of  claim 78 , wherein the bortezomib is administered at an intravenous dose of 1.3 mg/m 2 . 
     
     
         81 . The method of  claim 77 , wherein the anti-CS1 antibody is administered at an intravenous dose of 2.5 mg/kg. 
     
     
         82 . The method of  claim 77 , wherein the anti-CS1 antibody is administered at an intravenous dose of 5 mg/kg. 
     
     
         83 . The method of  claim 77 , wherein the anti-CS1 antibody is administered at an intravenous dose of 10 mg/kg. 
     
     
         84 . The method of  claim 77 , wherein the patient receives the anti-CS1 antibody once every 10 days. 
     
     
         85 . The method of  claim 84 , wherein the patient receives the bortezomib four times in a three week cycle. 
     
     
         86 . The method of  claim 85 , wherein the bortezomib is given on days 1, 4, 8, and 11 followed by a 10 day rest period. 
     
     
         87 . A method of treating multiple myeloma in a subject concurrently on a regimen of two therapeutic agents that consist of dexamethasone and bortezomib, comprising administering a therapeutically effective amount of an anti-CS1 antibody that binds the epitope cluster covered by amino acids 170 to 227 of SEQ ID NO:1 to the subject. 
     
     
         88 . The method of  claim 87 , wherein the anti-CS1 antibody is a humanized IgG 1  antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6. 
     
     
         89 . The method of  claim 88 , in which the anti-CS1 antibody is administered intravenously at a dose from approximately 0.5 mg/kg to approximately 20 mg/kg. 
     
     
         90 . The method of  claim 88 , in which the anti-CS1 antibody is administered intravenously at a dose of approximately 10 mg/kg. 
     
     
         91 . The method of  claim 88 , wherein the bortezomib is administered twice weekly over a 21 day cycle followed by a 10 day rest period. 
     
     
         92 . The method of  claim 88 , wherein the anti-CS1 antibody is administered as an intravenous infusion at a dose from 2.5 mg/kg to 20 mg/kg and wherein the bortezomib is administered as an intravenous infusion at a dose from 0.2 mg/m 2  to 2.0 mg/m 2 . 
     
     
         93 . The method of  claim 92 , wherein the bortezomib is administered at an intravenous dose from 1.0 mg/m 2  to 1.3 mg/m 2 . 
     
     
         94 . The method of  claim 93 , wherein the bortezomib is administered at an intravenous dose of 1.0 mg/m 2 . 
     
     
         95 . The method of  claim 93 , wherein the bortezomib is administered at an intravenous dose of 1.3 mg/m 2 . 
     
     
         96 . The method of  claim 92 , wherein the anti-CS1 antibody is administered at an intravenous dose of 2.5 mg/kg. 
     
     
         97 . The method of  claim 92 , wherein the anti-CS1 antibody is administered at an intravenous dose of 5 mg/kg. 
     
     
         98 . The method of  claim 92 , wherein the anti-CS1 antibody is administered at an intravenous dose of 10 mg/kg. 
     
     
         99 . The method of  claim 92 , wherein the patient receives the anti-CS1 antibody once every 10 days. 
     
     
         100 . The method of  claim 99 , wherein the patient receives the bortezomib four times in a three week cycle. 
     
     
         101 . The method of  claim 100 , wherein the bortezomib is given on days 1, 4, 8, and 11 followed by a 10 day rest period.